Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation that produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at presentation. The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all phases of CML and is the standard of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Swords, Ronan, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Carew, Jennifer, Giles, Francis
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769239/
https://www.ncbi.nlm.nih.gov/pubmed/19920925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769239/
https://www.ncbi.nlm.nih.gov/pubmed/19920925

Ejemplares similares